Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00434967 |
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Candesartan cilexetil Drug: Hydrochlorothiazide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind, Randomised, 4-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults |
Enrollment: | 1506 |
Study Start Date: | January 2007 |
Study Completion Date: | February 2008 |
Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: No Intervention
Placebo
|
|
2: Active Comparator
Candesartan cilexetil
|
Drug: Candesartan cilexetil
32 mg oral tablet
|
3: Active Comparator
Hydrochlorothiazide
|
Drug: Hydrochlorothiazide
25 mg oral tablet
|
4: Experimental
Candesartan cilexetil + Hydrochlorothiazide Combination
|
Drug: Candesartan cilexetil
32 mg oral tablet
Drug: Hydrochlorothiazide
25 mg oral tablet
|
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Belgium | |
Research Site | |
Gozée, Belgium | |
Research Site | |
Dour, Belgium | |
Research Site | |
Marchovelette, Belgium | |
Research Site | |
Ronquières, Belgium | |
Research Site | |
Linkebeek, Belgium | |
Research Site | |
Steenokkerzel, Belgium | |
Research Site | |
Saint-Médard, Belgium | |
Research Site | |
Hasselt, Belgium | |
Latvia | |
Research Site | |
Riga, Latvia | |
Research Site | |
Daugavpils, Latvia | |
Research Site | |
Ogre, Latvia | |
Malta | |
Research Site | |
Gozo, Malta | |
Research Site | |
Gwardiamangia, Malta | |
Romania | |
Research Site | |
Arad, Romania | |
Research Site | |
Bucuresti, Romania | |
Research Site | |
Targoviste, Romania | |
Research Site | |
Ploiesti, Romania | |
Research Site | |
Timisoara, Romania | |
Research Site | |
Pitesti, Romania | |
Research Site | |
Iasi, Romania | |
Russian Federation | |
Research Site | |
Moscow, Russian Federation | |
Research Site | |
St. Petersburg, Russian Federation | |
Slovakia | |
Research Site | |
Levice, Slovakia | |
Research Site | |
Lucenec, Slovakia | |
Research Site | |
Sahy, Slovakia | |
Research Site | |
Presov, Slovakia | |
Research Site | |
Bratislava, Slovakia |
Study Director: | Michael Klibaner, MD | AstraZeneca |
Principal Investigator: | Istvan Edes, MD | DEOEC Institute of Cardiology |
Study ID Numbers: | D2456C00002, EudraCT No. 2006-003963-30 |
Study First Received: | February 13, 2007 |
Last Updated: | February 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00434967 |
Health Authority: | Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment |
Blood pressure reduction combination therapy candesartan cilexetil hydrochlorothiazide |
Candesartan cilexetil Candesartan Vascular Diseases |
Angiotensin II Hydrochlorothiazide Hypertension |
Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Natriuretic Agents Therapeutic Uses Sodium Chloride Symporter Inhibitors |
Physiological Effects of Drugs Diuretics Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |